TCWM
SEEL

Total Clarity Wealth Management’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Total Clarity Wealth Management’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1
Closed -$5K – 1072
2021
Q3 		$5K Buy
+1
New +$8.59K ﹤0.01% 831
2021
Q2 		– Sell
-1
Closed -$10K – 786
2021
Q1 		$10K Buy
+1
New +$11.7K 0.01% 572

Other funds holding SEEL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Total Clarity Wealth Management's SEEL Position: Q4 2021 in Review

Total Clarity Wealth Management sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2021, closing a stake of 1 share — an estimated $5K sold.

Total Clarity Wealth Management first reported a position in SEEL in Q1 2021 and held it in 2 quarters. The position peaked at $10K in Q1 2021. 82 funds tracked by Wall St. Rank hold SEEL as of Q4 2021.

  • Total Clarity Wealth Management reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Total Clarity Wealth Management sold 1 Seelos Therapeutics, Inc. Common Stock share in Q4 2021, an estimated $5K.
  • Total Clarity Wealth Management first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
  • Total Clarity Wealth Management's Seelos Therapeutics, Inc. Common Stock position peaked at $10K in Q1 2021.
  • 82 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Total Clarity Wealth Management's 13F filing for Q4 2021, filed 3 Feb 2022.